Abstract
The uniflagellate protozoan parasite Trypanosoma brucei multiplies extracellularly in blood and escapes elimination by the complement system. Activated complement elicits potent biological activities including direct lysis of pathogens (Mollnes et al., 2002; Song et al., 2000; Walport, 2001). One strategy adopted by pathogens to avoid clearance and destruction by complement is to acquire host fluid-phase regulators, like C4b-binding protein or factor H. The acquisition of fluid-phase regulators on the surface of a given pathogen normally results in downregulation of complement activation.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hresko, S., Mlynarcik, P., Pulzova, L., Bencurova, E., Mucha, R., Csank, T., Madar, M., Cepkova, M., Bhide, M., 2012. Rapid protein production pipeline in advanced inducible Leishmania tarentolae expression system. Farm animal proteomics: 75-79.
Mollnes, T.E., Song, W.C. and Lambris, J.D., 2002. Complement in inflammatory tissue damage and disease. Trends Immunol 23: 61-64.
Song, W.C., Sarrias, M.R. and Lambris, J.D., 2000. Complement and innate immunity. Immunopharmacology 49: 187-198.
Walport, M.J., 2001. Complement. First of two parts. N Engl J Med 344: 1058-1066.
Acknowledgements
This work was supported by competitive academic grants APVV-0036-10 and VEGA–1/0054/12.
Author information
Authors and Affiliations
Corresponding author
Editor information
Rights and permissions
Copyright information
© 2013 Wageningen Academic Publishers
About this paper
Cite this paper
Dolinska, S. et al. (2013). Trypanosoma brucei brucei binds human complement regulatory protein C4BP. In: de Almeida, A., et al. Farm animal proteomics 2013. Wageningen Academic Publishers, Wageningen. https://doi.org/10.3920/978-90-8686-776-9_35
Download citation
DOI: https://doi.org/10.3920/978-90-8686-776-9_35
Publisher Name: Wageningen Academic Publishers, Wageningen
Online ISBN: 978-90-8686-776-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)